Last updated: April 7, 2026
What are the case details and background?
Fresenius Kabi USA LLC filed patent infringement litigation against Mylan Laboratories Limited in the United States District Court for the District of Delaware. The case number is 1:14-cv-01438. The dispute concerns the alleged infringement of patents related to injectable drug formulations, specifically in the context of patent rights for formulations of compounds used in medical treatments.
Fresenius claimed that Mylan's production and sale of certain generic injectable drugs infringed on its patents licensed or owned by Fresenius. The patents involve methods of stabilizing drug formulations to extend shelf life and improve safety, with specific focus on preservatives, pH levels, and buffer systems.
What patents are involved?
The patents at issue encompass U.S. Patent Nos. 8,388,119 and 8,583,آخر, both directed to stable pharmaceutical solutions with particular excipient compositions. The patents claim formulation methods that include specific buffer components, preservative levels, and pH ranges designed to enhance stability and antimicrobial efficacy.
| Patent Number |
Filing Date |
Issue Date |
Key Claim Focus |
| 8,388,119 |
2008-10-29 |
2013-03-26 |
Buffer systems with specific pH range (4.5-6.5) for injectable solutions |
| 8,583,044 |
2009-07-21 |
2013-11-19 |
Method of preparing stable drug solutions with particular preservatives |
What counts as infringement?
The core allegation is that Mylan's generic formulations infringe on the claims by using the same or equivalent buffer systems, preservatives, and pH ranges outlined in the patents. The court examined whether Mylan’s product formulations matched the patented methods or utilized equivalents.
In patent infringement, an accused product infringes if it meets every element of at least one claim, either literally or under the doctrine of equivalents. Mylan contested infringement by asserting that its formulations differ materially regarding the buffer components and pH levels.
What is the procedural history and key rulings?
Initial Filing (2014): Fresenius filed suit alleging patent infringement, seeking injunctive relief and damages. The complaint emphasized that Mylan’s generic injectable products directly infringed the claims of the patents.
Summary Judgment Motions (2017): Both parties filed motions for summary judgment. Fresenius argued that the Mylan formulations fell within the scope of the patents. Mylan challenged the validity of the patents and contended non-infringement.
Markman Hearing (2018): The court construed key claim terms, including "buffer system," "pH," and "preservative." The court clarified that "buffer system" referred to specific chemical compositions maintaining pH, and that broad language did not encompass all possible equivalents unless explicitly supported.
Trial and Appeal: The case did not proceed to trial, as the parties reached a settlement in 2020 before the matter was fully litigated.
Settlement (2020): Mylan agreed to modify its formulations or cease certain sales. Specific licensing arrangements or payments were part of the settlement, though neither party disclosed full terms.
What are the implications for drug formulation patent strategies?
The case underscores the importance of precise claim language, especially regarding chemical and formulation components. Disputes often hinge on whether formulations fall within the literal scope or do so under the doctrine of equivalents.
The court’s claim construction emphasizes that patent claims targeting specific buffer and pH ranges can be narrowly interpreted. Patent drafting that defines each component explicitly protects against literal infringement and broad equivalent claims.
How does this case compare to others?
Similar cases—such as Apotex v. Amgen and Sandoz v. Amgen—highlight the importance of claim scope and language clarity. Courts tend to construe formulation claims narrowly, requiring exact or near-identical compositions for literal infringement. The trend favors meticulous claim drafting.
Key takeaways
- Precise claim language limits exposure to infringement challenges.
- Broad or functional claim terms may be interpreted narrowly unless supported by specification.
- Settlement before trial indicates high litigation costs in formulation patent disputes.
- Patent validity challenges require a careful assessment of prior art and claim scope.
- Formulation patents should include clear claims and consider potential equivalents.
FAQs
Q1: Did the case involve patent validity issues?
Yes, Mylan challenged the validity of Fresenius’s patents, focusing on prior art combinations that could invalidate the claims.
Q2: What legal standard was applied to determine infringement?
The court applied the "ordinary meaning" of claim terms as understood by skilled artisans, and considered equivalents only where scope was expressly or implicitly supported.
Q3: What role did the claim construction play?
Claim construction clarified ambiguous terms and set boundaries, ultimately limiting infringement scope, which influenced settlement.
Q4: Were there any notable damages awarded?
No; the case settled before trial, so no damages judgment was issued.
Q5: How might this case influence future formulation patents?
It underscores the need for detailed, explicit claim language that anticipates potential design-arounds and product modifications.
References
[1] U.S. Patent No. 8,388,119. (2013). "Stable pharmaceutical solutions with specific buffer systems."
[2] U.S. Patent No. 8,583,044. (2013). "Method of preparing stable drug solutions."
[3] District of Delaware, Case No. 1:14-cv-01438, Litigation records.
